Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed-dose combination lercanidipine/enalapril.

Philip I Hair1, Lesley J Scott, Caroline M Perry

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Fixed-dose lercanidipine/enalapril effectively treats hypertension unresponsive to monotherapy. This combination therapy significantly lowers blood pressure with a well-tolerated safety profile compared to individual agents.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Lercanidipine (dihydropyridine calcium channel blocker) and enalapril (ACE inhibitor) are established antihypertensive drugs.
  • A fixed-dose combination tablet of lercanidipine/enalapril is approved in Germany for treatment-resistant hypertension.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of fixed-dose lercanidipine/enalapril in hypertensive patients.
  • To compare the combination therapy against monotherapy with either lercanidipine or enalapril.

Main Methods:

  • Two 12-week, randomized, double-blind trials were conducted.
  • Patients with mild to moderate hypertension unresponsive to monotherapy were included.
  • Blood pressure reduction was measured in sitting position.

Related Experiment Videos

Main Results:

  • Lercanidipine/enalapril 10mg/10mg significantly reduced systolic and diastolic blood pressure compared to lercanidipine 10mg monotherapy.
  • Lercanidipine/enalapril 10mg/20mg was more effective than enalapril 20mg monotherapy in reducing blood pressure.
  • The fixed-dose combination was well tolerated, with adverse events similar to monotherapy or placebo.

Conclusions:

  • Fixed-dose lercanidipine/enalapril is an effective treatment option for hypertension.
  • The combination therapy offers improved blood pressure control in patients not responding to monotherapy.
  • The drug combination demonstrates a favorable safety and tolerability profile.